Abstract | AIMS: METHODS: RESULTS: Nine of 16 patients treated with itraconazole capsules and eight of 15 treated with the solution responded to treatment. Three of the non-responders in each treatment group were infected with isolates resistant to itraconazole in vitro. Although with both preparations there was considerable inter-patient variability in the maximum recorded serum concentrations of itraconazole, they were significantly lower on day 1 and day 7 in those receiving capsules compared with those taking the solution. Patients unresponsive to therapy, but infected with susceptible isolates, had significantly lower concentrations of itraconazole and hydroxyitraconazole levels on days 1 and 7 than patients responding to treatment. However, patients infected with itraconazole resistant isolates (tested in vitro) failed to respond to treatment despite achieving similar serum concentrations of itraconazole and hydroxy- itraconazole to the responsive patients. For patients with in vitro susceptible isolates a serum itraconazole concentration of < 1000 ng/ml on day 7 was predictive of therapeutic failure (specificity 71%, sensitivity 100%). CONCLUSIONS:
|
Authors | J D Cartledge, J Midgely, B G Gazzard |
Journal | Journal of clinical pathology
(J Clin Pathol)
Vol. 50
Issue 6
Pg. 477-80
(Jun 1997)
ISSN: 0021-9746 [Print] England |
PMID | 9378812
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- Capsules
- Solutions
- hydroxyitraconazole
- Itraconazole
|
Topics |
- AIDS-Related Opportunistic Infections
(blood, drug therapy)
- Antifungal Agents
(administration & dosage, blood)
- Candidiasis, Oral
(drug therapy)
- Capsules
- Chemistry, Pharmaceutical
- Cohort Studies
- Humans
- Itraconazole
(administration & dosage, analogs & derivatives, blood)
- Male
- Solutions
|